Assembly Biosciences
Dr. Gane is Professor of Medicine at the University of Auckland, New Zealand, Hepatologist and Deputy Director of the New Zealand Liver Unit at Auckland City Hospital.
Dr. Gane trained in hepatology at the Institute of Liver Studies, King’s College School of Medicine, London, where he completed his MD on the pathogenesis of hepatitis C-related liver injury. In 1998, Dr. Gane was appointed as Chief Physician for the first New Zealand Liver Unit at Auckland City Hospital, which provides a national transplant and HCC programme. Dr Gane helped set up the community-based national HBV Surveillance Programme, which is the largest in the world. He now chairs the Ministry of Health committee responsible for HCV elimination.
Dr. Gane is an investigator for many international clinical trials with particular interest in early phase development of new direct acting antiviral therapies against chronic hepatitis C, hepatitis B, NASH and HCC. He has published almost 350 papers in peer-reviewed journals including The Lancet and The New England Journal of Medicine.
In 2011, Dr. Gane was awarded Member of the Order of New Zealand for Services to Medicine and in 2017, was New Zealand Innovator of the Year for his work towards HCV elimination in New Zealand. In 2018, he was elected to the Royal Society of Medicine (New Zealand).
This person is not in the org chart
This person is not in any offices
Assembly Biosciences
9 followers
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets.